ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular ...(hpatient was hospitalized for cardiovasc...),Health

Date:11/6/2007

h patient was hospitalized for cardiovascular of heart failure causes). Moreover, Dr. Carson presented data that the pairing of these two favorable genotypes produces an even greater clinical response than either monotype alone. With this pairing, all-cause mortality was reduced by 41% (p = 0.032), cardiovascular mortality by 48% (p = 0.017), adjudicated time to first cardiovascular or heart failure hospitalizations by respectively 33% (p =0.008) and 45% (p = 0.002), and days hospitalized/patient by 32% (cardiovascular, p =0.012) or 36% (heart failure, p = 0.003). Such patients, termed the "very favorable diplotype," comprising over 40% of the general population, will be the highest priority for treatment with bucindolol.

New Data on Bucindolol in Atrial Fibrillation and Ventricular Arrhythmia

Data from the Phase 3 BEST clinical trial (Presentation #2867) demonstrated a positive effect of bucindolol on clinically important arrhythmic conditions-atrial fibrillation (AF) and life threatening ventricular arrhythmias (VT/VF). In the presentation by Christopher Lowery, M.D. of the University of Colorado, subjects with chronic heart failure (CHF) and Arg/Arg 389 beta-1 or wild type alpha-2c adrenergic receptors treated with bucindolol had a lower rate of new onset AF than those randomized to placebo. This treatment effect was not observed in the population of beta-1 Gly389 or the alpha-2c deletion carriers, indicating a pharmacogenetic interaction. Moreover, the "Very Favorable" diplotype pairing of these two favorable gene variants produced even greater positive treatment effects (reduction by 52%, p = <0.048), similar to the pharmacogenetic findings observed with heart failure endpoints.

As demonstrated in a presentation (Presentation #2021/C32) by William Sauer, M.D. of the University of Colorado, subjects with CHF and Arg/Arg 389 beta-1 or wildtype alpha2c adrenergic receptors treated with bucindolol had a lower rate of VT/VF than those randomized to
'/>"/>

SOURCE ARCA Discovery, Inc. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice